MK-2214 Drug Trial for people with early Alzheimer's disease

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease. The goal of the study is to learn if MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD & damages brain cells.

People who meet the following criteria my be eligible to participate in the study; 

• Aged 50 to 85 years 
• Have a diagnosis of Mild Cognitive Impairment or Mild Alzheimer's dementia
• Have a study partner who can come onsite for a few hours every 3 months
• No other neurological condition

This trial goes for 2.4 years and involves monthly infusions. Participants will also need to have MRIs, PET scans, blood tests, and cognitive testing.